AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase II study titled ‘A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)’. The study aims to assess the efficacy of a chemotherapy-free regimen in newly diagnosed mantle cell lymphoma patients, focusing on achieving a minimal residual disease-negative complete response.
The study tests a combination of three drugs: acalabrutinib, a Bruton’s Tyrosine Kinase inhibitor; venetoclax, a BCL2 inhibitor; and rituximab, an anti-CD20 monoclonal antibody. This combination is intended to provide an effective treatment option without the use of traditional chemotherapy.
The study is interventional with a single-group assignment, open-label design, and no masking. Its primary purpose is treatment, focusing on the efficacy of the drug combination in achieving complete response in participants.
The study began on December 13, 2023, and is currently active but not recruiting. The last update was submitted on June 26, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
This clinical update could influence AstraZeneca’s stock performance positively, as successful results may enhance the company’s oncology portfolio. Investors should monitor the study’s outcomes, especially in the competitive landscape of lymphoma treatments, where innovative therapies are in demand.
The study is ongoing, and further details are available on the ClinicalTrials portal.